Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMO | Q99835 | 17/20 | 0.74 |
| ▸ | SLC6A7 | Q99884 | 2/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | GFER | P55789 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4183815 | 1.00 | SMO (0.74) | SMOSLC6A7MEN1GFERKMT2A | |
| SCHEMBL3700114 | 0.91 | SMO (0.66) | SMOSLC6A7 | |
| SCHEMBL3700116 | 0.91 | SMO (0.66) | SMOSLC6A7 | |
| SCHEMBL1102317 | 0.90 | SMO (0.69) | SMOSLC6A7 | |
| SCHEMBL1089997 | 0.90 | SMO (0.67) | SMOSLC6A7 | |
| SCHEMBL4171980 | 0.90 | SMO (0.69) | SMOSLC6A7 | |
| SCHEMBL1090000 | 0.90 | SMO (0.67) | SMOSLC6A7 | |
| SCHEMBL2272698 | 0.89 | SMO (0.59) | SMOSLC6A7MEN1GFERKMT2A | |
| SCHEMBL1091112 | 0.85 | SMO (1.00) | SMO | |
| SCHEMBL1091116 | 0.85 | SMO (1.00) | SMO |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2170866-B1 | PHTHALAZINE COMPOUNDS, COMPOSITIONS AND METHODS OF USE | AMGEN INC (US) | 2014-08-13 | — | — | EP | disclosed |
| US-8153633-B2 | Phthalazine compounds, compositions and methods of use | AMGEN INC. (US) | 2012-04-10 | — | — | US | disclosed |
| US-8153633-B2 | Phthalazine compounds, compositions and methods of use | AMGEN INC. (US) | 2012-04-10 | — | — | US | disclosed |
| US-20090048259-A1 | Phthalazine compounds, compositions and methods of use | AMGEN INC. (US) | 2009-02-19 | — | — | US | disclosed |
| US-20090048259-A1 | Phthalazine compounds, compositions and methods of use | AMGEN INC. (US) | 2009-02-19 | — | — | US | disclosed |
| US-20090048259-A1 | Phthalazine compounds, compositions and methods of use | AMGEN INC. (US) | 2009-02-19 | — | — | US | disclosed |
| WO-2009002469-A1 | PHTHALAZINE COMPOUNDS, COMPOSITIONS AND METHODS OF USE | AMGEN INC. (US) | 2008-12-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090048259-A1 | Phthalazine compounds, compositions and methods of use | VHL, HDAC5, SUZ12 | SMO 520/4885SLC6A7 1030/4885MEN1 471/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.